Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2023)

PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826

Caceres, Valeria

Más información

Título según WOS: PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826
Título de la Revista: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volumen: 33
Editorial: Elsevier
Fecha de publicación: 2023
Página de inicio: A1
Página final: A1
DOI:

10.1136/ijgc-2023-ESGO.1
Notas: ISI